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Abstract
The Global Vaccine Action Plan proposes that every country establish or have access to a National
Immunization Technical Advisory Group (NITAG) by 2020. The NITAG role is to produce evidence-
informed recommendations that incorporate local context, to guide national immunization policies
and practice. This study aimed to explore the value and effectiveness of NITAGs in low- and
middle-income countries (LMICs), identifying areas in which NITAGs may require further support
to improve their functionality and potential barriers to global investment. A multi-methods study
design was used, comprising 134 semi-structured interviews and 82 literature review sources that
included 38 countries. Interviews were conducted with 53 global/regional and 81 country-level par-
ticipants able to provide insight into NITAG effectiveness, including NITAG members, national im-
munization programme staff, and global agency representatives (e.g. the World Health
Organisation, the Bill and Melinda Gates Foundation, Gavi the Vaccine Alliance). The review,
including published and unpublished sources on NITAGs in LMICs, was conducted to supplement
and corroborate interview findings. Data were analysed thematically. NITAGs were described as
valuable in promoting evidence-informed vaccination decision-making, with NITAG involvement
enhancing national immunization programme strength and sustainability. Challenges to NITAG
effectiveness included: (1) unreliable funding; (2) insufficient diversity of member expertise; (3) in-
adequate conflicts of interest management procedures; (4) insufficient capacity to access and use
evidence; (5) lack of transparency; and (6) limited integration with national decision-making proc-
esses that reduced the recognition and incorporation of NITAG recommendations. LMIC NITAGs
have developed significantly in the past decade. Well-functioning NITAGs were trusted national
resources that enhanced country ownership of immunization provision. However, many LMIC
NITAGs require additional technical and funding support to strengthen quality and effectiveness,
while maintaining impartiality and ensuring sufficient integration with national decision-making
processes. Barriers to sustainable global support need to be addressed for LMIC NITAGs to both
continue and develop further.
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Background
To promote strong and sustainable national immunization pro-
grammes, the Global Vaccine Action Plan outlined a 2020 target for
all countries to establish or have access to a National Immunization
Technical Advisory Group (NITAG) (WHO, 2013). NITAGs are
multi-disciplinary bodies of national experts, aiming to provide im-
partial evidence-based recommendations to guide vaccination
decision-making by policy-makers and programme managers
(Duclos, 2010). NITAGs are intended to encourage country owner-
ship of immunization programmes by promoting decision-making
based on national context, considering factors such as local epidemi-
ology, resource availability, cost-effectiveness and programme sus-
tainability (Duclos, 2010; SIVAC, 2012). Given competing demands
on health resources and increasing numbers of new vaccines in low-
and middle-income countries (LMICs), the NITAG approach is con-
sidered important for determining whether programme recommen-
dations made at global or regional levels are optimal at country-
level (Duclos, 2010).
By the end of 2016, 58% of WHO member states (119/194) had
a legally or administratively mandated NITAG (WHO/UNICEF,
2018), a 45% increase from 78/194 in 2010 (WHO, 2016a; SAGE,
2017). NITAG performance, as measured by six process indicators
included in the WHO/UNICEF Joint Reporting Form (JRF) also
improved over time (Duclos, 2010). JRF indicators were: (1) legisla-
tive/administrative basis; (2) formal written terms of reference; (3)
membership expertise across at least five areas of paediatrics, public
health, infectious diseases, epidemiology, immunology, other; (4) at
least one meeting annually; (5) agenda and background documents
available to NITAG members at least 1 week prior to meetings; and
(6) requiring members to declare conflicts of interest. In 2016, 83
NITAGs globally—a 42% increase from 2010 (WHO, 2017)—
reported meeting the six JRF indicators.
NITAG progress is particularly notable in LMICs (SAGE, 2017).
Between 2010 and 2016, the number of WHO member states
reporting a NITAG with a legislative or administrative basis
increased from 7% (2/30) to 52% (16/31) in low-income countries
and from 41% (43/101) to 61% (67/109) in middle-income coun-
tries (SAGE, 2017; WHO/UNICEF, 2018). Similarly, the number
reporting a NITAG meeting the six JRF performance criteria
increased from 3% (1/30) to 35% (11/31) in low-income countries
and from 19% (20/101) to 39% (42/109) in middle-income coun-
tries (SAGE, 2017; WHO/UNICEF, 2018).
To support NITAG establishment and strengthening in LMICs,
the Bill and Melinda Gates Foundation funded Agence de Me´decine
Pre´ventive and International Vaccine Institute to implement the
Supporting Independent Immunization and Vaccine Advisory
Committees (SIVAC) Initiative from 2008 to 2017 (AMP, 2018;
Howard et al., 2018a; Senouci et al., 2010). SIVAC provided
advocacy and partnership development, direct support to NITAG
development and strengthening, and indirect NITAG capacity build-
ing through materials, publications and tools development (Senouci
et al., 2010). This study aimed to explore the value and effectiveness
of NITAGs in LMICs, drawing on data from an evaluation of
SIVAC support. Objectives were to: (1) describe NITAGs’ role and
value, (2) examine elements contributing to NITAG effectiveness,
particularly those requiring additional support, and (3) explore po-
tential barriers to global stakeholder investment in NITAGs.
Methods
Study design and country eligibility
A qualitative multi-methods study design including semi-structured
interviews with global and national informants and a narrative re-
view of published and unpublished literature. Interviews and litera-
ture findings were compared during data analysis and interpretation
to increase comprehensiveness.
Country eligibility, for national interviews and literature review,
was determined by: (1) Gavi eligibility in 2008, or World Bank
LMIC status in 2008 plus any reported SIVAC support 2008–17;
and (2) JRF reported NITAG in 2016. Thus, among 77 Gavi-eligible
and 44 SIVAC-supported LMICs, 55 reported a legally established
NITAG in 2016 and were eligible for inclusion.
Data collection
Semi-structured interviews were conducted in 2017 with (1) global/
regional and (2) country-level key informants. Global interviewees
included members of technical partner agencies, e.g. WHO, the Bill
and Melinda Gates Foundation, US-CDC, Gavi, and high-income
NITAGs that hosted LMIC NITAG visits. Members of high-income
country NITAGs were interviewed about their mentoring and sup-
port to specific LMIC NITAGs rather than to discuss their own
NITAG. Country-level interviewees included NITAG chairpersons,
NITAG secretariat, core and ex-officio members (e.g. WHO,
UNICEF) and national stakeholders (e.g. immunization programme
managers). Interviewees were approached and recruited via email or
at international meetings. Interviews were conducted by NH, HW
or SMJ in English, French, Russian or Spanish, either face-to-face or
by telephone, at times and places selected by interviewees.
Interviews lasted approximately 40 minutes, were audio-recorded,
and transcribed professionally.
The literature review, conducted in early 2017, included eligible
LMICs reporting a NITAG in 2016. First, seven databases were
searched systematically from January to March: Medline (Ovid);
Embase (Ovid); Global Health (Ovid); Social Policy and Practice
(Ovid); Dissertations and Theses in UK and Ireland and Theses
Global (ProQuest); Global Index Medicus (bvsalud.org); and
Virtual Health Library Regional Portal (bvsalud.org). Searches were
conducted in French, Portuguese and Spanish on ProQuest and
Key Messages
• Authors drew from 134 global and national-level semi-structured interviews and 82 literature sources that included 38
low- and middle-income countries (LMICs) to provide a broad and robust assessment of perceived National
Immunization Technical Advisory Group (NITAG) value, effectiveness and functionality.
• Well-functioning NITAGs appear to be trusted national resources that enhance country ownership of immunization pro-
vision, but many LMIC NITAGs require additional support to maintain/strengthen effectiveness.
• If the global community wishes to preserve and strengthen the NITAG decision-making model in LMICs, it needs to rec-
ognize existing challenges and mobilize investment to support these country-owned advisory bodies.
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bvsalud.org. Keywords and their synonyms were: NITAG, vaccine,
immunization, advisory, expert, technical, committee.
Secondly, references and websites were hand-searched in March.
Hand-searched references and websites included the Vaccine special
issue on NITAGs [Vaccine, vol. 28(Suppl. 1), 2010]; the NITAG
Reference Centre website; WHO and IRIS websites; US-Centers for
Disease Control and Prevention Morbidity and Mortality Weekly
Report website; reference lists of journal articles included in the re-
view; reference list from a SAGE-commissioned NITAG literature
review (John, 2010); and sources obtained from interviewees.
Table 1 provides full eligibility criteria. Eligible sources were pub-
lished between 2006 and 2017 (to cover the period of SIVAC activ-
ity), in English, French, Portuguese or Spanish (to cover the
languages of most publication on NITAGs in LMICs), and were
journal articles, evaluation reports, PowerPoint presentations or ad-
ministrative forms (e.g. legal documents, operating procedures).
Duplicates were removed and titles, abstracts and eligible full
texts screened using EPPI-Reviewer 4 (v4.6.4.0). Screening was per-
formed by LB, with NH double-screening 5% of titles and abstracts
(N¼82) and SB double-screening 33% of full texts (N¼70).
Discrepancies were below 5% and resolved by author discussion.
Double-screening of a proportion of sources was conducted to en-
sure rigour while maintaining timeliness and efficiency, as this was a
narrative rather than systematic review and inclusion criteria were
relatively straightforward (i.e. sources discussed NITAGs in
included countries).
Analysis
Interview data were analysed thematically by NH, SB, HW and
SMJ, supported by NVivo version 11, using the stages outlined by
Braun and Clarke (2006). Authors used an abductive approach,
with deductive codes taken from the interview guide and inductive
codes coming from transcript data. Deductive and inductive themes
were: (1) NITAG role and value; (2) NITAG functionality/effective-
ness; (3) NITAG challenges and enablers; and (4) NITAG
achievements.
Literature data were independently extracted by LB and SB,
using a 23-category framework developed from the SIVAC tool for
evaluating NITAGs (HPID, 2016) plus publication year, type,
authors’ affiliations and country described. Two authors synthesized
data narratively, including descriptive statistics and illustrative
quotes, into five themes: (1) NITAG scope and functions; (2)
NITAG management of conflicts of interest; (3) NITAG capacity to
use evidence; (4) NITAG transparency; and (5) NITAG linkages
with the Ministry of Health. Discrepancies were resolved through
author discussion.
Results
Scope and themes
Table 2 shows 134 interviews were conducted, 53 global/regional
and 81 national. Global interviewees included members of technical
partner and donor agencies, e.g. WHO, the Bill and Melinda Gates
Foundation. National interviewees, including NITAG and national
immunization programme representatives, were recruited from 24
countries across five WHO regions (i.e. WHO Office of the
Americas region interviews were not organized before study
completion).
Figure 1 shows 82 literature sources were identified, referring to
NITAGs in 31 countries. Only 13% were empirical research or
NITAG evaluations, with the remainder descriptive, e.g. opinion
articles and administrative documents. Most (80%) were authored
by NITAG members or government entities.
The two overarching themes explored below are: (1) perceived
NITAG role and value; and (2) NITAG effectiveness and key per-
ceived challenges. Funding security, identified as the primary
Table 1. Literature review eligibility criteria
Criteria Included Excluded
Language English, French, Spanish and Portuguese Other languages
Publication year From January 2006 to May 2017 Before 2006 and after May 2017—sources published before
2006 were excluded as: (1) NITAGs were first mentioned
in a WHO Regional Technical Advisory Group report on
immunization in 2006; (2) only four NITAGs from
included countries were established before 2006
Organization NITAGs Committees other than NITAGs
Country LMICs reporting a NITAG in 2016 JRF report Other countries
Themes • Scope and functions;
• Relationships with Ministry of Health;
• Transparency;
• Conflict of interest; and
• Capacity to use evidence.
• Not about human vaccination and
• About other themes.
Publication type • Journal articles;
• Conference abstracts;
• Evaluation reports from any organization;
• Descriptive reports from any organization (excluding meeting
reports);
• Presentations (e.g. PowerPoint);
• NITAG procedures, policies, decrees, nominations, member
lists mentioning professions and activity reports;
• Governmental reports and plans, e.g. NITAG procedures, poli-
cies, decrees, nominations, member lists mentioning profes-
sions; and
• SAGE minutes.
• Meeting agendas, attendance sheets, minutes;
• NITAG agreements, work-plans, financial documents,
training materials, news, newsletters;
• Mission reports, workshop reports, study tour reports;
• Nominations, allocutions, member lists not mentioning
professions;
• NITAG meeting minutes; and
• NITAG recommendations.
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challenge to the existence and effectiveness of LIMC NITAGs, is
explored further in Howard et al. (2018a).
Perceived NITAG role and value
Interviewees described NITAGs’ role as promoting vaccination pol-
icy and programme decision-making based on evidence, rather than
opinions or lobbying pressure. Although the NITAG role was most
often described as providing guidance on applying global and re-
gional recommendations at country-level, extended NITAG roles
were also reported. These included direct involvement in the investi-
gation of vaccination-related adverse events, providing disease
prevalence and vaccination surveillance data, and indirect involve-
ment in bio-safety and human resources. NITAG decision-making
sometimes went beyond new vaccines, such as NITAGs working to
improve national immunization programme credibility and public
confidence. For example, an interviewee described how a NITAG’s
recommendation was actively disseminated to address vaccine hesi-
tancy and concerns raised by anti-vaccine activists. In the longer
Table 2. Interviewees and literature sources, by global organization and/or country
Organizational affiliations (n ¼ 28) of 53 global
interviewees
WHO regions (n ¼ 6) Countries (n ¼ 38)a Interviewees by
country (n ¼ 81)
Literature sources
by country (n ¼
85)e
AMP (Agence de Me´decine Pre´ventive) Regional Office for
Africa (AFRO)
Benin 2 4
AMP-SIVAC (Supporting Independent Immunization and
Vaccine Advisory Committees) Initiative
Burkina Faso 2 3
Cote d’Ivoire 3 11
Ethiopia 2 0
BMGF (Bill and Melinda Gates Foundation) Kenya 0 1
Mali 0 1
ECDC (European Centre for Disease Control) Mozambiqueb 2 7
Nigeria 12 5
Gavi, the Vaccine Alliance Senegal 9 10
Global Health Task Force Tanzania 1 0
NICE international Togo 0 1
MOH-Ghana Uganda 9 7
NITAG-Australia Zambia 1 0
NITAG-Belgium Zimbabwe 2 0
NITAG-Canada Regional Office for
the Americas
(PAHO)
Honduras 0 3
NITAG-France Nicaraguac 0 1
NITAG-Germany
NITAG-Netherlands Regional Office for
the Eastern
Mediterranean
(EMRO)
Pakistan 3 0
NITAG-UK Tunisiad 2 6
NITAG-USA
PROVAC (Promotion of Evidence-Based Decision-Making
on New Vaccine Introductions) Regional Office for
Europe (EURO)
Albania 2 0
Armenia 5 6
US-CDC (US-Centers for Disease Control and Prevention) Kazakhstand 1 4
Kyrgyzstan 0 3
VENICE (Vaccine European New Integrated Collaboration
Effort)
Regional Office for
South East Asia
(SEARO)
Moldova 0 2
Bangladesh 0 2
WAHO (West African Health Organisation) Bhutan 0 1
WHO-Headquarters India 2 14
WHO-AFRO Indonesia 13 8
WHO-AFRO/RITAG (Regional Immunisation Technical
Advisory Group)
Myanmar 2 1
Nepal 1 5
WHO-ESA (Eastern and Southern Africa sub-region) Sri Lanka 1 4
Timor-Leste 1 2
WHO-EURO Regional Office for
the Western Pacific
(WPRO)
China 1 4
WHO-PAHO Cambodiac 0 2
WHO-SEARO Lao People’s
Democratic
Republic
0 1
WHO-WPRO Mongolia 0 1
Philippinesd 2 2
Viet Nam 0 1
aSeventeen additional eligible countries (i.e. Afghanistan, Azerbaijan, Bosnia and Herzegovina, Cameroon, Cuba, Democratic Republic of the Congo, Djibouti,
Georgia, Malawi, Mauritania, Niger, South Sudan, Sudan, Tajikistan, Ukraine, Uzbekistan, Yemen) reported NITAGs in 2016, but no country-level interviews
could be conducted or literature sources located.
bMozambique was incorrectly listed as not having a NITAG in the 2016 JRF, so still included in findings.
cLiterature for Cambodia and Nicaragua described quasi-NITAGs and were not included in findings.
dNot Gavi-eligible in 2008, but received SIVAC support.
eSome sources cover multiple countries, so the total does not equal 82.
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term, many NITAG members indicated that revising and broadening
the scope of the NITAG was preferable to disbanding as they still
saw a valuable role for NITAGs.
The role of NITAGs should not be limited to the consideration
of recommendations for the introduction of new vaccines, but
should extend to devising strategies for optimizing the use of
existing vaccines and strengthening national immunization pro-
grammes (Country 25-1).
Literature sources described several NITAG as having additional
roles and varying degrees of involvement in implementation and
operations, from the development of guidance on practical aspects
of vaccine introduction (Ba-Nguz et al., 2017) and cold chains
(Molina-Aguilera et al., 2010), to addressing ‘bottlenecks’ in pro-
gramme delivery (John, 2010). Additionally, some NITAGs were
involved in research (Ba-Nguz et al., 2017; John, 2010; Molina-
Aguilera et al., 2010). The role of the Sri Lankan NITAG was excep-
tionally broad, covering all communicable diseases, not just those
that are vaccine-preventable (Wijesinghe et al., 2010). This NITAG
had unusual decision-making power, including revising the national
immunization schedule, approving funding mobilization and intro-
ducing new vaccines (Wijesinghe et al., 2010).
Interviewees were asked specifically about the value of NITAGs.
Many reported that there had been a degree of scepticism towards
NITAGs in the early years of SIVAC support, in part due to concerns
that NITAGs might delay vaccine introduction. Over time, however,
NITAGs were increasingly regarded by the majority of interviewees as
essential for effective vaccination policy and programme decision-
making, as they became more embedded in national policy-making
processes and providing independent, evidence-based recommendations.
The role of the NITAG is very important. For example, the min-
istry made the decision to introduce the HPV vaccine but without
involving the NITAG. The introduction did not go well and there
were major issues of acceptability and resistance, ending up with
only two regions with a low coverage rate. There were a lot of
negative comments on the vaccine. After that the Ministry of
Health arranged for the NITAG to play a bigger and more sub-
stantive role (Country 15-1).
Without NITAGs, interviewees noted that decision-making was
not necessarily evidence-based and vaccination programmes were
more likely to be sub-optimal, unsustainable and open to undue in-
fluence or even corruption.
. . .prior to NITAG formation in many countries globally, par-
ticularly middle and low-income countries and I would argue
gnineercS
dedulcnI
noitacifitnedI
Excluded (n = 1,471)
Language (n = 5)
< 2006 (n = 797)
Country (n = 184)
Not on human vaccinaon (n =50)
Not on NITAGS/other naonal advisory 
groups (n = 286)
Type of publicaon (n = 102)
Duplicates (n = 47)
Excluded (n = 128)
Language (n = 4)
Country (n = 1)
Not on NITAGS/other naonal advisory 
groups (n = 56)
Type of publicaon (n = 22)
No details on NITAG processes (n = 40)
Duplicates (n = 4)
Not available (n = 1)
Records idenﬁed through database 
searching 
(n = 2,693)
Records eligible for screening 
at tle and abstract level 
(n = 1,681)
Addional records idenﬁed via other 
sources (websites, personal contacts, etc.) 
(n = 126)
Records aer duplicates removed 
(n = 1,555)
Full-texts screened 
(n = 210)
Papers included 
(n = 82)
Figure 1. PRISMA flow diagram of literature search.
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even, in the olden days, some high-income countries too, many
of those decisions were driven by manufacturers and not driven
by evidence, by local vaccine preventable disease data, not driven
by how the healthcare system was set up. . . (Global 10).
NITAG effectiveness
NITAG members generally described their NITAG as well-
functioning, although several interviewees noted that self-reported
JRF functionality criteria were insufficient to fully capture NITAG
effectiveness. SIVAC (2016a) describes NITAG effectiveness as
encompassing functionality, quality, and integration and all three
aspects were deemed important by interviewees.
They [NITAGs] have to be independent but they also have to
have the expertise to do all the work. So, if they are just inde-
pendent but don’t have the expertise to do the quality, they don’t
have the structures to do the quality, it doesn’t matter [. . .] So,
you need function; you need quality, and you need integration.
You need all three of these. . . (Global 10).
Interviewees reported that substantial input was required to en-
sure effectiveness after NITAG establishment.
Setting up NITAGs should be a long-term enterprise as it
involves developing a culture of evidence-based policy over many
years. In high-income countries, this has taken many decades and
we should not expect any differently from low-income countries.
It is not a two-year project, but rather a 20-year investment.
(Global 12).
NITAG members described several support mechanisms that
improved their effectiveness, including capacity-building trainings
and access to relevant materials. Additionally, they described visits
to other NITAGs—especially to well-established NITAGs in high-
income countries—as particularly beneficial to learn about
NITAGs’ role and functionality, increase motivation and instil pride
in their work.
[the NITAG] Chairman and other members visited a well-
functioning NITAG, [. . .] and before that, as me, they don’t real-
ise what is a NITAG. They didn’t even recognise their role in the
NITAG, and it helped, especially for the Chair of the NITAG.
Now she’s very proud that she is Head of the NITAG, yeah,
[after] experiencing the well-functioning NITAG (Country 2-3).
Effectiveness was reported as varying depending on context,
NITAG maturity, and the type of support received. Key areas dis-
cussed as potential challenges included: (1) membership; (2) con-
flicts of interest; (3) transparency; (4) capacity to gather and use
evidence; (5) national recognition and integration within decision-
making bodies; and (6) funding security.
Expertise and diversity of NITAG members
Member expertise and diversity affect NITAG functional capacity.
NITAGs aimed to be representative, at least in terms of member ex-
pertise and, sometimes other factors, e.g. geographical diversity.
Interviewees noted this as challenging for NITAGs in smaller coun-
tries with limited numbers of experts and suggested an alternative
could be sharing a NITAG between several countries.
. . .. some countries are probably too small to have a NITAG, by
which I mean finding an adequate number of external experts
might be very difficult. In which case it’s possible that countries
would need to, several small countries would need to band to-
gether to have a NITAG (Global 42).
The most frequently mentioned area of missing expertise for
NITAGs was health economics. The literature revealed that less
than half of 24 NITAGs reporting this information had a member
with economic expertise. While economic expertise is not included
in JRF criteria, many NITAG members indicated its importance. A
few NITAGs that lacked economists as members sought external
support (Molina-Aguilera et al., 2010; Wijesinghe et al., 2010), an
approach recommended by Duclos (2010).
Secretariat capacity was another issue that significantly affected
the quality of NITAG processes. Interviewees discussed the import-
ance of a strong secretariat to provide support. For example,
NITAGs with only one secretariat member, even a very capable one,
reported struggling to ensure functionality and manage workload.
. . .. a strong secretariat, meaning it should be well staffed and, in
our view. . .. having more than one person full-time, but secondly,
that we should have a mix of skill-sets in the Secretariat. . .
(Country 41-1).
Conflict of interest processes
A key feature of NITAG functional capacity is a formal conflict of
interest policy with robust procedures to ensure independence from
government and other parties with specific agendas, such as vaccine
manufacturers.
[The NITAG] role is extremely important because they need to
be totally independent and specifically from the conflicts of inter-
est, particularly from the big pharma [. . .] at country level
(Global 14).
Interviewees highlighted the need for NITAGs to report and ad-
dress conflicts of interests, although not all NITAGs had adopted
formalized conflict of interest policies.
We are revising the terms of reference, introducing conflict of
interest because in the past terms of reference, there was just a
statement that conflict of interest should be applied, but actually
it was not done (Country 2-2).
Literature sources identified conflict of interest information for
16 NITAGs, with all but one reporting some form of conflict of
interest policy or procedures. However, conflict of interest import-
ance and processes were not universally understood. For instance,
reticence to implement conflict of interest policies was noted in
Nepal (Schmitt & Batmunkh, 2014), while the Sri Lankan NITAG
described the rationale for conflict of interest reporting as public
transparency rather than independence of decision-making
(Wijesinghe et al., 2010). NITAG members were generally requested
to declare any conflict of interest at the start of meetings, and several
had processes to address conflicts of interest when declared
[Ministry of Health (Mali), 2014; National Primary Health Care
Development Agency (NPHCDA) (Nigeria), 2015]. However, infor-
mation on implementation was scarce. For example, Cote d’Ivoire
reported using declaration forms ‘when necessary’ (Benie Bi, 2015),
while in Honduras members with conflicts of interest were tempor-
arily suspended and prohibited from voting (Molina-Aguilera et al.,
2010). Literature sources were critical of interest groups attempting
to influence NITAG decision-making, such as medical associations
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(Molina-Aguilera et al., 2010). For example, Gavi’s promotion of
HPV vaccination in India was described as: ‘. . .interest groups
attempting to push all available vaccines into the national pro-
grammes regardless of needs, practical and cost-effectiveness consid-
erations’ (Jayakrishnan, 2013).
For several NITAGs, interviewees and literature sources noted
that scarcity of experts could sometimes make it difficult to avoid
including any NITAG members engaged at some level with the vac-
cine industry, e.g. serving as board members (Schmitt and
Batmunkh, 2014). Conversely, some interviewees noted that con-
flicts of interest could be managed effectively by using the appropri-
ate procedures and NITAGs could also be a force for independence,
with one NITAG member describing how their country resisted
Ministry of Health pressure to procure a less cost-effective vaccine.
Capacity to gather and use evidence
Though crucial for the quality of NITAG processes, the capacity to
collect, synthesize and interpret scientific evidence reportedly varied
considerably. Interviewees noted that NITAG members often did
not have sufficient time to engage thoroughly with evidence collec-
tion, review and interpretation. Additionally, some NITAG mem-
bers reported difficulties in accessing literature, with paywalls and
publication language reported as barriers—a finding also noted in
country evaluation literature (SIVAC, 2016a).
It is not right to assume that because they are experts in their
areas, then they know enough to continue to effectively function
as NITAG members. They need capacity building and facilitating
access to the right information in immunisation, so that then they
are in a better position to guide the Ministries of Health. This
should be an important part of our work of establishing
NITAGs, to continually build the capacity of these people and
provide updated information for them to function properly
(Global 17).
Several interviewees commented that more training of NITAG
members was needed to help them collect and evaluate evidence.
I think one of the problems that all NITAGs suffer with is assem-
bly of evidence and so I think that’s probably one of the import-
ant areas to have support (Global 43).
Little documented evidence was found of NITAG literature
searching and use, despite this process being essential to NITAGs’
role. Of nine NITAGs for which some data were available, two
appeared to conduct structured literature searches (Zheng et al.,
2010; NITAG, 2015), three appeared to have detailed standardized
processes to analyse evidence and develop recommendations (Ba-
Nguz et al., 2017; NITAG, 2015; Uganda National Academy of
Sciences, 2016), and four appeared to miss one or more crucial step
(Molina-Aguilera et al., 2010; SIVAC, 2016b, 2016c; Wijesinghe
et al., 2010). Interviews indicated a preference for using local data
and the need to make this readily accessible to NITAGs.
If we don’t find any [local data], we use the regional data. If there
were not any regional data, we use the global data or something
like that. So, the important thing is, if possible we use first local,
regional and global (Country 14-16).
However, both interviewees and literature sources noted that
local data might not be available. Of 11 countries describing access
in literature sources, 7 reported access and 4 reported limited access.
Members typically used their affiliation with universities and hospi-
tals to source and report local evidence or relied on links with local
partners (Ba-Nguz et al., 2017; Makinen et al., 2012; Wijesinghe
et al., 2010). Access to national economic evaluations varied. Of
nine NITAGs reporting access information, four sometimes used na-
tional economic evaluations (Makinen et al., 2012; Wijesinghe
et al., 2010) and five had limited or no access to them (Durupt,
2015; Makinen et al., 2012; SIVAC, 2016a).
Literature sources provided information on type of data used for
12 NITAGs. Epidemiology, disease burden, economic evaluation
and WHO recommendations data were most commonly reported,
followed by affordability and financial sustainability, vaccine avail-
ability and supply, and clinical characteristics or vaccine effective-
ness. A few mentioned socio-economic, cultural and equity
considerations or recommendations by other NITAGs. While sour-
ces were unclear about how NITAGs incorporated social and equity
considerations into recommendations, they indicated NITAG
decision-making was informed by more than clinical data.
Transparency
Transparency can improve public trust in vaccination programmes
and integration with national decision-making. Literature sources
advocate transparency approaches such as open meetings and pub-
lishing meeting minutes and recommendations (Duclos, 2010), al-
though interviewees and literature indicated this was not always
implemented. Interviewees discussed the importance of ensuring
that NITAG processes were transparent, to instil greater public and
professional confidence in vaccination programmes.
In large part, but not all, there has grown the suspicion that there
may be collusion links between private interest and a decision
taken. It is even more important than ever that the decision and
the expertise are separated and that’s something that I think we
have achieved in many EU countries. This is one of the most im-
portant reasons to have a well-functioning NITAG, not only be-
cause a decision will be the right one, but also because it will be
perceived as such by the health professionals and by the pop-
ulation. . . (Global 38).
For the 12 NITAGs for which access to NITAG meetings was
reported, literature sources indicated that most permitted observa-
tion by non-members—primarily external experts—upon request
(SIVAC, 2016b; Wijesinghe et al., 2010) or by invitation [Ministry
of Health (Cote d’Ivoire), 2009; John, 2010; Molina-Aguilera et al.,
2010; Wijesinghe et al., 2010; Ministry of Health (Mongolia), 2011;
Ministry of Health (Kazakhstan), 2012; Schmitt & Batmunkh,
2014; Uganda National Academy of Sciences, 2014; NPHCDA
(Nigeria), 2015; SIVAC, 2016b; Hadinegoro et al., 2017]. Although
external attendance was possible in principle, it was unclear how
frequently access to meetings by non-members occurred and
whether external parties were aware of the possibility of attending
meetings.
For the 14 NITAGs for which access to minutes or recommenda-
tions were reported, literature sources indicated most were inaccess-
ible to the public [Molina-Aguilera et al., 2010; Wijesinghe et al.,
2010; Zheng et al., 2010; Ministry of Health (Kazakhstan), 2012;
Schmitt & Batmunkh, 2014; Uganda National Academy of Sciences,
2014; NPHCDA (Nigeria), 2015; Durupt, 2016; SIVAC, 2016c;
Hadinegoro et al., 2017]. Literature sources only mentioned two
NITAGs routinely providing publicly available minutes and recom-
mendations (John, 2010), while another reported meeting minutes
as available upon request (SIVAC, 2016b). In practice, documents
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described as open access were often unavailable (e.g. not on web-
sites, inaccessible due to broken links, only available for certain
meetings or years) or difficult to locate. Some NITAG reports were
described as only disseminated by the Ministry of Health (Zheng
et al., 2010) or ‘made public after Ministry of Health approbation’
(Nepal National Committee on Immunization Practices, 2010),
which potentially limits transparency, e.g. if the Ministry of Health
did not agree with NITAG recommendations.
Integration with national decision-making
Acknowledgement of NITAGs’ role and contributions by national
influencers and interaction with decision-makers were considered
crucial to NITAG integration within decision-making processes and
overall effectiveness (MacDonald et al., 2017). Acknowledgement
included awareness of NITAGs’ role, usage of member’s expertise,
and implementation and dissemination of NITAG recommenda-
tions. Most NITAGs achieved a good level of Ministry of Health
recognition, as reported by both NITAG and Ministry of Health
interviewees.
Many members of the NITAG have been invited in several meet-
ings [at the Ministry of Health. . .]. So, I think it’s a very good
achievement for them, because their performance is being recog-
nised (Country 14-23).
However, interviewees reported that NITAG interactions with
decision-makers could often be hindered by lack of integration with
government, potentially lessening likely adoption of NITAG recom-
mendations. In some cases, NITAG efforts to maintain independ-
ence from government prevented the links necessary to ensure
adoption of recommendations.
It can’t be totally independent. The independence should come
about from. . . ‘My recommendation for this vaccine is not based
on my connection with a pharmaceutical company, or any money
that I’m going to make from it,’ but it doesn’t mean that it has to
be dissociated from the government (Global 31).
Literature sources identified a broad range of approaches to
NITAG communication with government, from embedding
NITAGs within government structures (Wijesinghe et al., 2010) to
having no government NITAG members or formal relationship with
government (SIVAC, 2016b). However, many NITAGs reported
having Ministry of Health or government representatives as mem-
bers. While Duclos and others recommend that for policy support
Ministry of Health representatives be ex-officio members without
decision-making powers (Duclos, 2010), this was often not the case.
For example, the Sri Lankan NITAG was chaired by a government
official (Wijesinghe et al., 2010). Government decrees and members
did not automatically imply formal communications and interac-
tions. Four NITAGs did not disseminate recommendations directly
to Ministry of Health, either because recommendations were listed
in minutes with no recommendation document prepared [Nepal
National Committee on Immunization Practices (NCIP), 2010;
Ministry of Health (Kyrgyzstan), 2012; Durupt, 2015; Durupt,
2016], or because recommendations were submitted via an inter-
mediate (Durupt, 2015).
Interviewees and literature sources indicated that NITAGs need
independence from government while maintaining a formal relation-
ship (Duclos, 2010). This tension between independence and inte-
gration was described by interviewees as a careful balance of
ensuring NITAGs had sufficient government links to be relevant
while maintaining independence from government influence in pro-
ducing recommendations.
. . ..[the NITAG] can’t be totally independent. The independence
should come about from. . . my recommendation for this vaccine
is not based on my connection with a pharmaceutical company,
or any money that I’m going to make from it. But it doesn’t
mean that it has to be dissociated from the government (Global
31).
Interviewees reported that although health ministries broadly
adopted NITAG recommendations, implementation delays often
occurred, particularly if NITAG deliberations did not examine cost-
effectiveness or other policy concerns took precedence.
We have delays in the implementation of our recommendations
because often there are issue of affordability for the government.
The introduction of this vaccine has gone up the list—we have a
list of priority vaccines to be introduced when finance allows.
PCV is at the top, then pertussis for pregnant woman, then Rota
and HPV (Country 40-2).
For example, while it was difficult to assess the timing of recom-
mendations in relation to Gavi grant applications, interviewees indi-
cated that Gavi vaccine introductions were not always reviewed by
NITAGs. This seemed particularly the case for vaccines requiring a
rapid decision (e.g. Gavi funding ending for transitioning countries).
Several NITAGs reported producing a high number of adopted
recommendations (e.g. Mozambique, Sri Lanka) and interviewees
indicated governments were increasingly requesting NITAG recom-
mendations, e.g. in response to emerging disease threats or out-
breaks. For example, Mozambique recommended implementation
of cholera vaccination. Interviewees described NITAGs influencing
national policies, with several highlighting that recommendations
were adapted to local context (e.g. birth-dose HepB; dengue;
RTS, S) in terms of schedule, target population, or programmatic
and financial realities.
. . ..the country was going to introduce probably the [Merck] vac-
cine that’s three doses, and then when they did it, a NITAG re-
view changed it to the two-dose . . . [GSK] vaccine (Global 33).
NITAG members’ capacity to leverage individual affiliations
(e.g. medical associations, private providers) and personal connec-
tions with important stakeholders (e.g. policy-makers, influencers)
added to NITAGs’ potential influence.
Further global investment
The most significant challenge to NITAG establishment and
strengthening raised by interviewees was the ending of SIVAC’s sup-
port, described by almost all interviewees as crucial to LMIC
NITAG development and strengthening. A related challenge was ac-
cess to sustainable funding and technical support, as no global sup-
port mechanism was immediately apparent as SIVAC funding ended
(Howard et al., 2018a). Most interviewees considered that at least
some financing should come from national governments, though in-
dependence of NITAG decision-making must be ensured.
The reasons given why the global community had so far failed to
fill this gap, despite expressed need by both global and national
stakeholders, varied from lack of interest/awareness to other prior-
ities to scepticism. Some interviewees suggested that global partners
were not equally committed to NITAGs and that without SIVAC’s
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momentum NITAGs might ‘fall under the radar’ of key global agen-
cies. Global interviewees suggested various reasons for this. Several
criticized SIVAC for not planning post grant, e.g. by developing
more sustainable partnerships and making SIVAC’s and NITAGs’
achievements more visible. Some described the persistent scepticism
of a few influential global actors regarding the value of NITAGs in
low-income countries and ‘lip service’ paid by many in the inter-
national community to country ownership (e.g. as country processes
might delay or derail vaccine introduction timelines). Others raised
concerns about the uneven perceived performance of existing
NITAGs, in terms of the length of time they might continue to re-
quire external support. A few discussed perceived confusion be-
tween regional and national technical advisory groups for
immunization and ongoing lack of role clarity, e.g. about which
body should be doing what and which was the best body for global
partners to support.
Discussion
Despite limitations, much progress has been achieved by LMIC
NITAGs in the past 10 years of global health community support
(SAGE, 2017). NITAGs appear unique in being independent yet for-
mal expert committees that are integrated to varying degrees within
government decision-making, an innovative approach compared
with other vertical disease programmes (e.g. HIV country co-ordi-
nating mechanisms, Ministry of Health linked technical sub-
committees for tuberculosis and malaria). This study provides a
comprehensive exploration of the value and effectiveness of LMIC
NITAGs, and is the first to include such a broad sample of national,
regional and global perspectives.
These findings support previous research showing NITAGs are
valued for delivering independent evidence-based recommendations
to guide national vaccination decision-making (Duclos, 2010;
SAGE, 2017; World Health Assembly, 2017). Findings indicate
NITAGs were particularly valued for their capacity to strengthen
country ownership and inspire public confidence. NITAGs’ primary
role involves reviewing the evidence base on vaccines, assessing local
data and adapting global or regional recommendations to national
contexts. NITAGs’ scope varies, reflecting national history, degree
of sophistication and capacity—potentially extending from recom-
mending new vaccines and schedules to roles in monitoring and
evaluating immunization safety and programme performance.
Better integrating NITAGs into Ministry of Health decision-
making is critical to NITAG relevance, and findings indicated vari-
ability related to country context, governance and NITAG capacity
to achieve Ministry of Health recognition. Duclos and colleagues
recommend that NITAGs have a direct link with senior Ministry of
Health officials (Duclos, 2014). However, specific guidance is lack-
ing on how to establish and maintain links, with NITAGs adopting
various approaches (MacDonald et al., 2017). SAGE has thus called
for developing best practice guidelines (SAGE, 2017). Particularly in
countries with higher-functioning NITAGs, Ministries of Health val-
ued the NITAG’s role and independence, suggesting its scope could
extend to broader oversight of the immunization programme and, in
some cases, using its independent expertise as a public voice for pro-
grammes. However, this could create tensions with other bodies,
e.g. immunization inter-agency co-ordinating committees that or-
ganize funding and implementation.
Determining NITAG effectiveness remains challenging, with
both interviewees and literature sources acknowledging the limita-
tions of JRF performance indicators. JRF indicators are useful
during NITAG setup, or as a snapshot of progress, and could be
adapted to provide better granularity for monitoring functionality
alongside, or complemented by, systematic evaluation exercises to
pinpoint specific areas for improvement (HPID, 2016). Interviewees
repeatedly noted that the development process for these new bodies
would take time, with effectiveness and gravitas improving with
maturity.
Determining NITAG policy impact is particularly challenging.
For example, simply measuring available numbers of recommenda-
tions could be deceptive, as recommendations are not always
adopted by policy-makers, while their absence could be due, con-
versely, to systematic review and evidence-based decision-making.
However, concurrent in-depth work in five countries (Howard
et al., 2018b) provided some convincing examples of evidence-based
recommendations that were translated into tailored country-level
policy, along with Ministry of Health requests for NITAG recom-
mendations and contributions. Nevertheless, it is important to note
that immunization policy decision-making remains complex, and
evidence-based components should be understood as one aspect of
broader political processes (Burchett et al., 2012). Thus impact is
difficult to evaluate.
Many challenges still face recently established LMIC NITAGs,
potentially reducing their effectiveness. These include standard oper-
ating procedures requiring further strengthening (i.e. conflict of
interest management, transparency), understaffed secretariats, mem-
ber expertise gaps—especially health economics and cost-
effectiveness review processes, and ongoing funding uncertainties.
Although significant progress has been made, findings showed many
NITAGs—notably those more recently established—remained fra-
gile and required further support to achieve the 2020 WHO Global
Vaccine Action Plan target (Howard et al., 2018a).
Vaccination programme and NITAG strengthening is particular-
ly crucial in LMICs, as these countries experience the greatest bur-
den of vaccine-preventable disease (WHO, 2013), the lowest
reported levels of vaccination coverage (WHO, 2013), large inequal-
ities in vaccination access (Restrepo-Me´ndez et al., 2016; WHO,
2016b), and long delays in the introduction of new vaccines (WHO,
2013). Thus, interviewees overwhelmingly argued for ongoing glo-
bal technical and financial support to LMIC NITAGs (Howard
et al., 2018a), some highlighting the need to prioritize countries
transitioning from Gavi funding while others argued for smaller and
lower-income countries (WHO, 2016a). The barriers within the glo-
bal community, noted by some interviewees, will need to be
addressed if sustainable global funding is to be mobilized.
Support could take many forms. Small countries might particu-
larly benefit from collaborating or combining with neighbouring
NITAGs to facilitate sharing of expertise (SAGE, 2017). Relatedly,
interviewees highlighted the benefits of visits between NITAGs and
the potential for broader knowledge-sharing efforts through the
Global NITAG Network. Many also advocated for more and better
resources, including strengthening NITAG Resource Centre (http://
www.nitag-resource.org/) capacity to facilitate access to technical
materials and encourage sharing of information and best practices.
Possible study limitations should be considered. These include
potential interviewee or source bias, such as NITAG members
reporting on their committee’s effectiveness, although the large and
diverse sampling frame helped mitigate this. Additionally, although
the literature review involved a systematic search, many documents
are not routinely shared and/or only produced in national languages,
and so not all potential sources could be accessed. The small propor-
tion of titles and abstracts screened in duplicate means that some
relevant documents might have been excluded, though screening
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criteria were straightforward enough that this was unlikely to be a
significant issue. Although authors included all eligible countries,
only 36 were covered by at least one interview or document, and
data for some were quite limited.
Conclusions
NITAGs have played an increasingly important, albeit disparate,
role in LMIC immunization decision-making over the past decade.
They are modelled on similar committees in high-income countries
that evolved over the past 50 years. Stakeholders at global, regional
and national levels recognize the value of NITAGs contributions to
evidence-based policy-making, particularly as countries have
adopted many new vaccines and vaccination represents a growing
national funding requirement. NITAGs face ongoing challenges,
and if the global community is to support this decision-making
model further, it needs to recognize these and mobilize investment
to support the capacity development and strengthening of these
country-owned advisory bodies.
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